TIMP2 and breast cancer: In detail, carriers of the TIMP-2 rs8179090 heterozygous variant CG and homozygous variant CC genotypes exhibited 1.16- and 2.76-fold increased ORs for BC risk, respectively, compared to individuals with the wild-type GG genotype (95%CI = 0.97–1.39 and 1.78–4.28, p = 0.1249 and 0.0001, respectively).